IlluminaXSWX:ILMN -0.79%76 Shareholder Yield % is 3.27% as of Mar. 2026, which is 4571% above its 10-year median of 0.07. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF105.51. The stock has 7 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Illumina ranks better than 77.83% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Illumina's Shareholder Yield % was 3.27%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Illumina Shareholder Yield % Related Terms
Illumina Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Illumina's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ILMN vs MTD, DGX, LH: Shareholder Yield % Comparison
For the Diagnostics & Research subindustry, Illumina's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Shareholder Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Illumina's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Illumina (XSWX:ILMN) has a Shareholder Yield % of 3.27% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Illumina and its competitors. This is 4571% above median its historical median of 0.07. According to the industry distribution chart, Illumina ranks #45 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 22.2%.
Is Illumina's Shareholder Yield % too high?
Illumina's current Shareholder Yield % of 3.27% is 4571% above median its 10-year median of 0.07. The Medical Diagnostics & Research industry median Shareholder Yield % is 0.02. Illumina's value of 3.27% is 16250% above this industry median. Based on the distribution chart, Illumina ranks #45 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Shareholder Yield % compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #45 out of 203 companies for Shareholder Yield %. This places Illumina in the top 22% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.02. Illumina's value of 3.27% is 16250% above this benchmark. While the company's 10-year median is 0.07 vs. the industry median of 0.02, Illumina has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Diagnostics & Research company?
The median Shareholder Yield % among Medical Diagnostics & Research companies is 0.02, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Illumina's current Shareholder Yield % of 3.27% is 16250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median Shareholder Yield % is 0.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current Shareholder Yield % is 3.27%, which is 4571% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Shareholder Yield % of 3.27%. The stock's GF Value™ is CHF105.51, compared to a current price of CHF143.95 — trading 36.4% above its estimated fair value. The current Shareholder Yield % is 3.27%, which is 4571% above median its 10-year median of 0.07 and 16250% above the Medical Diagnostics & Research industry median of 0.02. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Shareholder Yield % is 3.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF143.95 is trading 36.4% above its estimated GF Value™ of CHF105.51.
Key valuation signals for XSWX:ILMN:
Shareholder Yield %: 3.27% (4571% above median its 10-year median of 0.07)
GF Value™: CHF105.51 vs. price of CHF143.95 (36.4% above fair value)
Industry Position: 16250% above the Medical Diagnostics & Research median (#45 of 203)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
